{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4"},{"groupId":"OG001","value":"76.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"description":"Percentage of Participants with Progression Free Survival Events: progression, relapse, or death from any cause as assessed by an Independent Review Committee.","groups":[{"description":"Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \\[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).","id":"OG000","title":"Obinutuzumab + Chlorambucil (GClb)"},{"description":"Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.","id":"OG001","title":"Chlorambucil (Clb)"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population included all randomized participants. Participants without PFS events were censored.","reportingStatus":"POSTED","timeFrame":"Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)","title":"Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}